A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (NCT05117476)

🧪 Interventions in This Study

• CLN-619 (DRUG)
• Pembrolizumab (DRUG)
• Paclitaxel (DRUG)
• Carboplatin AUC 6 (DRUG)
• pemetrexed (DRUG)
• Datopotamab deruxtecan-dlnk (Dato-DXd) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (24 Sites)

• University of Alabama at Birmingham — Birmingham, Alabama
• City of Hope — Duarte, California
• City of Hope — Irvine, California
• Florida Cancer Specialists — Sarasota, Florida
• Dana-Farber Cancer Institute — Boston, Massachusetts
• START Midwest — Grand Rapids, Michigan
• Hackensack Meridian Health — Hackensack, New Jersey
• Memorial Sloan Kettering Cancer Center — New York, New York
• Carolina BioOncology Institute — Huntersville, North Carolina
• Sarah Cannon Research Institute — Nashville, Tennessee
• START San Antonio — San Antonio, Texas
• Virginia Cancer Center — Fairfax, Virginia
• Monash Health — Clayton, Victoria
• Alfred Health — Melbourne, Victoria
• Linear Clinical Research — Nedlands, Western Australia
• Biokinetica — Józefów,
• Med-Polonia Sp. zo. o. — Poznan,
• Narodowy Insytut Onkologii im Marii Sklodowskiej-Curie — Warsaw,
• Hospital Universitario Insular de Gran Canaria — Las Palmas de Gran Canaria, Gran Canaria
• START Barcelona — Barcelona,
• Hospital Clinic Barcelona — Barcelona,
• START Madrid FJD — Madrid,
• Clinica Universidad de Navarra — Pamplona,
• Hospital Universitari Parc Tauli — Sabadell,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumor

• Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
• A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
• QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
• A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
• First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
• A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas

Explore by condition: All Advanced Solid Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.